News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
Editorial Board
For Authors
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice Between the LinesContemporary ConceptsJournalOncViewPodcastsReadout 360Insights from Experts at Mayo Clinic on Translating Evidence to Clinical PracticeOptimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid LeukemiaBrain CancerBreast CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
Editorial Board
For Authors
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Melanoma
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Melanoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Treatment-Related Cardiotoxicity in Pediatric AML

November 16, 2018
Leah Lawrence
Article

A study looks at the occurrence of treatment-related cardiotoxicity and its impact on pediatric AML patients.

Pediatric patients with acute myeloid leukemia (AML) who experienced early treatment-related cardiotoxicity may have worse event-free survival and overall survival (OS), according to the results of the Children’s Oncology Group AAML0531 trial.

More than one in 10 patients experienced cardiotoxicity during a 5-year follow-up and of these, more than 70% of incident events happened during on-protocol therapy. Those patients with cardiotoxicity had significantly worse event-free and OS.

“Thus, efforts to improve outcomes for children with AML must include prevention and mitigation of on-protocol cardiotoxicity,” Kelly D. Getz, PhD, of the University of Pennsylvania, and colleagues wrote in The Journal of Clinical Oncology. “Such interventions may not only mitigate the impact of early cardiotoxicity but also late cardiotoxicity, which has been shown by multiple investigators to be the leading cause of late morbidity and non-relapse–related mortality in pediatric cancer survivors.”

The study looked at adverse events occurring in 1,022 pediatric patients with AML treated as part of COG AAML0531. This study enrolled patients aged 30 or younger and treated them with intravenous infusions of daunorubicin and mitoxantrone. Cardiotoxicity was defined as grade 2 or higher left ventricular systolic dysfunction (LVSD) on the basis of Common Terminology Criteria for Adverse Events definitions.

About 12% of patients had cardiotoxicity reported during a 5-year follow-up, and 71% of these events were first documented during on-protocol therapy. The median time to cardiotoxicity was 4.3 months. Documented on-protocol cardiotoxicity was significantly associated with subsequent off-protocol toxicity. Incidence of cardiotoxicity was higher among non-infants and black patients, and in the setting of bloodstream infections.

Patients with documented cardiotoxicity had significantly worse event-free survival (hazard ratio [HR], 1.6; 95% CI, 1.2–2.1; P = .004) and OS (HR, 1.6; 95% CI, 1.2–2.2; P = .005). Effects on event-free survival were similar for those with infection-associated LVSD and those with LVSD without infection.

Reductions in OS, however, were significantly worse for cardiotoxicity not associated with infection (HR, 1.7; 95% CI, 1.2–2.5; P = .004) than those with infection-associated cardiotoxicity (HR, 1.3; 95% CI, 0.7–2.4; P = .387).

“This dramatic decrease in event-free survival and resulting decrease in overall survival underscore the need to understand cardiotoxicity risk factors and to develop effective prevention strategies,” the researchers wrote.

Commenting on the results of the study, Steven E. Lipshultz, MD, FAAP, FAHA, Conger Goodyear Professor and chair of pediatrics, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, told Cancer Network that “the ability to help or harm children is real based on an understanding of this data and its implications.”

David Freyer, DO, director of survivorship and supportive care program at of the Children's Hospital of Los Angeles also commented on the study.

"This is an important study that adds new information in a large sample of high-risk patients about early predictors of long-term anthracycline-induced left ventricular dysfunction. It builds on what is already known about this problem and strengthens the case for prioritizing prospective clinical trials to study interventions for preventing this problem," said Freyer.

Related Videos
Ghayas C. Issa, MD, an expert on acute myeloid leukemia
Ghayas C. Issa, MD, an expert on acute myeloid leukemia
Mikkael A. Sekeres, MD, discusses how data from the phase 3 QuANTUM-First trial may advance the treatment field for patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.
An expert from Duke Health says that patients with NPM1-mutatant relapsed/refractory acute myeloid leukemia did not experience any significant safety signals following treatment with ziftomenib.
At the recommended 600 mg dose, ziftomenib interestingly produced complete remissions in patients relapsed/refractory acute myeloid leukemia who harbored NPM1 mutations .
An expert from Duke Health reviews the design of the phase 1/2 trial of the KOMET-001 study in heavily pretreated patients with relapsed/refractory acute myeloid leukemia.
Related Content
Advertisement

Adding all-trans retinoic acid to chemotherapy does not appear to improve complete remission rates compared with chemotherapy alone in patients with NPM1-mutated acute myeloid leukemia.

ATRA/Chemo Does Not Improve OS/Toxicity in NPM1+ Acute Myeloid Leukemia

November 3rd 2023
Article

Adding all-trans retinoic acid to chemotherapy does not appear to improve complete remission rates compared with chemotherapy alone in patients with NPM1-mutated acute myeloid leukemia.


Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.


Data from a phase 1 study support the orphan drug designation for SLS009 as a treatment for patients with acute myeloid leukemia.

SLS009 Earns FDA Orphan Drug Designation in Acute Myeloid Leukemia

October 12th 2023
Article

Data from a phase 1 study support the orphan drug designation for SLS009 as a treatment for patients with acute myeloid leukemia.


High Serum LDH Levels Confer Worse Survival in Newly Diagnosed AML | Image Credit: © LASZLO - stock.adobe.com.

High Serum LDH Levels Confer Worse Survival in Newly Diagnosed AML

October 10th 2023
Article

Elevated white blood cell counts also appear to correlate with shorter overall survival in patients receiving standard induction chemotherapy plus cytarabine for acute myeloid leukemia.


Data from the phase 3 ASCERTAIN trial support the European Commission’s approval of oral decitabine and cedazuridine as a treatment for those with newly diagnosed acute myeloid leukemia.

Decitabine/Cedazuridine Earns European Approval in Acute Myeloid Leukemia

September 21st 2023
Article

Data from the phase 3 ASCERTAIN trial support the European Commission’s approval of oral decitabine and cedazuridine as a treatment for those with newly diagnosed acute myeloid leukemia.


Adding all-trans retinoic acid to non-intensive chemotherapy appears to produce higher toxicity in elderly unfit patients with acute myeloid leukemia harboring NPM1 mutations.

ATRA/Chemo Yields Worse Outcomes in Elderly Unfit NPM1+ AML Population

September 19th 2023
Article

Adding all-trans retinoic acid to non-intensive chemotherapy appears to produce higher toxicity in elderly unfit patients with acute myeloid leukemia harboring NPM1 mutations.

Related Content
Advertisement

Adding all-trans retinoic acid to chemotherapy does not appear to improve complete remission rates compared with chemotherapy alone in patients with NPM1-mutated acute myeloid leukemia.

ATRA/Chemo Does Not Improve OS/Toxicity in NPM1+ Acute Myeloid Leukemia

November 3rd 2023
Article

Adding all-trans retinoic acid to chemotherapy does not appear to improve complete remission rates compared with chemotherapy alone in patients with NPM1-mutated acute myeloid leukemia.


Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.


Data from a phase 1 study support the orphan drug designation for SLS009 as a treatment for patients with acute myeloid leukemia.

SLS009 Earns FDA Orphan Drug Designation in Acute Myeloid Leukemia

October 12th 2023
Article

Data from a phase 1 study support the orphan drug designation for SLS009 as a treatment for patients with acute myeloid leukemia.


High Serum LDH Levels Confer Worse Survival in Newly Diagnosed AML | Image Credit: © LASZLO - stock.adobe.com.

High Serum LDH Levels Confer Worse Survival in Newly Diagnosed AML

October 10th 2023
Article

Elevated white blood cell counts also appear to correlate with shorter overall survival in patients receiving standard induction chemotherapy plus cytarabine for acute myeloid leukemia.


Data from the phase 3 ASCERTAIN trial support the European Commission’s approval of oral decitabine and cedazuridine as a treatment for those with newly diagnosed acute myeloid leukemia.

Decitabine/Cedazuridine Earns European Approval in Acute Myeloid Leukemia

September 21st 2023
Article

Data from the phase 3 ASCERTAIN trial support the European Commission’s approval of oral decitabine and cedazuridine as a treatment for those with newly diagnosed acute myeloid leukemia.


Adding all-trans retinoic acid to non-intensive chemotherapy appears to produce higher toxicity in elderly unfit patients with acute myeloid leukemia harboring NPM1 mutations.

ATRA/Chemo Yields Worse Outcomes in Elderly Unfit NPM1+ AML Population

September 19th 2023
Article

Adding all-trans retinoic acid to non-intensive chemotherapy appears to produce higher toxicity in elderly unfit patients with acute myeloid leukemia harboring NPM1 mutations.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.